NCT03606382 is a clinical trial of HostDx Fever Test in Acute Respiratory Infection, sponsored by Inflammatix.

Who is sponsoring NCT03606382?

NCT03606382 is sponsored by Inflammatix.

What drugs are being tested in NCT03606382?

Interventions in NCT03606382: HostDx Fever Test, HostDx Sepsis Test.

What condition does NCT03606382 study?

NCT03606382 studies Acute Respiratory Infection.

Is NCT03606382 still recruiting?

NCT03606382 is currently completed. Last updated 23 September 2019.

Last reviewed 2019-09-23 · How we verify

NCT03606382

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Collection of Clinical Specimens From Volunteers for Assay Development

Completed Last updated 23 September 2019

What this trial tests

trial testing HostDx Fever Test in Acute Respiratory Infection in 6 participants. Completed in 1 May 2019.

Timeline

1 April 2018

Primary endpoint
1 May 2019

1 May 2019

Quick facts

Lead sponsor	Inflammatix
Status	Completed
Study type	OBSERVATIONAL
Enrollment	6
Start date	1 April 2018
Primary completion	1 May 2019
Estimated completion	1 May 2019
Sites	1 location across United States

Drugs / interventions tested

HostDx Fever Test
HostDx Sepsis Test

Conditions studied

Acute Respiratory Infection — all drugs for Acute Respiratory Infection →

Sponsor

Inflammatix

Who can join

1 and older, any sex, with Acute Respiratory Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will analyze gene expression data from various biological specimens collected from voluntary participants.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Acute Respiratory Infection

Currently open trials in the same condition.

NCT06271655 — Rapid Diagnosis of Viral Acute Respiratory Infection to Decrease Unnecessary Antibiotic Utilization in the Emergency Dep · NA · active not recruiting
NCT06379542 — Efficacy and Safety of XC8, Film-coated Tablets, in Children With Acute Respiratory Viral Infections · Phase 3 · recruiting
NCT05814237 — POS-ARI-ER Observational Study of Acute Respiratory Infections · recruiting
NCT04099082 — Signature of the Host Response to a Respiratory Viral Infection, in the Prediction of Bronchiolitis Obliterans · recruiting

Other Inflammatix trials

Trials by the same sponsor.

NCT06637904 — TriVerity™ for Improved Management of Emergency Department (ED) Patients With Suspected Infections · NA · recruiting
NCT04414189 — Clinical Validation of HostDx Sepsis™ on NanoString; a Prospective Observational Validation Trial · completed
NCT04094818 — TriVerity in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections and Suspected Sepsis · completed
NCT03744741 — HostDx Sepsis in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections: a Multicenter P · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03606382 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Inflammatix
Last refreshed: 23 September 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03606382.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing